Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.
作者信息
Prasad Vinay, Kaestner Victoria, Mailankody Sham
机构信息
Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, Oregon.
出版信息
JAMA Oncol. 2018 Feb 1;4(2):157-158. doi: 10.1001/jamaoncol.2017.4182.
PMID:29285544
Abstract
摘要
Zotero 插件